Currently, the diagnostic panel for CRC comprises MSI/mismatch repair (MMR) status, KRAS/NRAS, BRAF, and PIK3CA mutations, and HER2 amplification [111]. This evidence concerns the gene KRAS and colorectal carcinoma.